Ginsenoside Rd: A promising target for ischemia-reperfusion injury therapy (A mini review) - 04/02/24
Abstract |
Ischemia-reperfusion injury (IRI) represents a prevalent pathological phenomenon. Traditional treatment approaches primarily aim at restoring blood supply to ischemic organs, disregarding the consequent damage caused by IRI. Belonging to the class of protopanaxadiol ginsenosides that are found in Panax ginseng, ginsenoside Rd (GSRd) demonstrates notable safety alongside a diverse range of biological functions. Its active components exhibit diverse pharmacological effects, encompassing anti-inflammatory, anti-tumor, neuroprotective, cardiovascular-protective, and immune-regulatory properties, making it a promising candidate for addressing multiple medical conditions. GSRd shields against I/R injury by employing crucial cellular mechanisms, including the attenuation of oxidative stress, reduction of inflammation, promotion of cell survival signaling pathways, and inhibition of apoptotic pathways. Additionally, GSRd regulates mitochondrial function, maintains calcium homeostasis, and modulates the expression of genes involved in I/R injury. This review seeks to consolidate the pharmacological mechanism of action of GSRd within the context of IRI. Our objective is to contribute to the advancement of GSRd-related pharmaceuticals and provide novel insights for clinicians involved in developing IRI treatment strategies.
Le texte complet de cet article est disponible en PDF.Highlights |
• | GSRd is a prospective therapeutic agent for cerebral/spinal cord/myocardial/renal IRI and Ischemic Insult. |
• | The certain precise mechanisms remain unknown. |
• | Ginsenosides should be taken with care due to the certain toxicity. |
• | Ginsenosides affect intracellular processes by binding to membrane receptors or diffusion. |
Keywords : Ginsenoside Rd, Ischemia reperfusion injury, Pharmacological effects, Research progress, Molecular mechanisms
Plan
Vol 171
Article 116111- février 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?